UBS Group
APGE icon

UBS Group’s Apogee Therapeutics APGE Stock Holding History

UBS Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.3M Buy
1,144,328
+169,502
+17% +$12.3M 0.01% 1080
2025
Q4 		$73.6M Buy
974,826
+175,361
+22% +$11M 0.01% 1260
2025
Q3 		$31.8M Buy
799,465
+692,308
+646% +$26.4M 0.01% 2069
2025
Q2 		$4.65M Sell
107,157
-594,752
-85% -$22.6M ﹤0.01% 3965
2025
Q1 		$26.2M Buy
701,909
+160,623
+30% +$6.21M ﹤0.01% 2092
2024
Q4 		$24.5M Buy
541,286
+489,466
+945% +$25M ﹤0.01% 2124
2024
Q3 		$3.04M Buy
51,820
+1,330
+3% +$63.7K ﹤0.01% 3571
2024
Q2 		$1.99M Sell
50,490
-25,541
-34% -$1.24M ﹤0.01% 3773
2024
Q1 		$5.05M Buy
+76,031
New +$3.32M ﹤0.01% 2961
2023
Q4 		– Sell
-3,557
Closed -$75.8K – 9271
2023
Q3 		$75.8K Buy
+3,557
New +$78.4K ﹤0.01% 6025

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS Group's APGE Position: Q1 2026 in Review

UBS Group increased its Apogee Therapeutics (APGE) stake by 17% in Q1 2026, buying an estimated $12.3M and bringing the position to 1,144,328 shares worth $96.3M. The position accounts for 0.01% of the portfolio, ranked #1080.

UBS Group first reported a position in APGE in Q3 2023 and has held it in 10 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • UBS Group held 1,144,328 shares of Apogee Therapeutics worth $96.3M as of Q1 2026.
  • UBS Group bought 169,502 Apogee Therapeutics shares in Q1 2026, an estimated $12.3M.
  • Apogee Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1080 holding.
  • UBS Group first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.